Literature DB >> 2652234

Pneumococcal pneumonia.

J D Coonrod1.   

Abstract

Pneumococci remain the most common cause of community-acquired pneumonia, and there are still important questions concerning the pathogenesis, management, and prevention of this disease. Infection begins by aspiration of pneumococci from the oropharynx. Alveolar macrophages, granulocytes, and extra-cellular factors, including opsonins, are necessary for control of bacterial proliferation and cure of the infection. Clinically, pneumococcal pneumonia often presents with sudden onset of productive cough, fever, and a rigor, but symptoms may be muted in the young, elderly, or debilitated. About one-fourth of patients have a positive blood culture. Examination of sputum by Gram's stain and culture can provide useful information, but are not definitive. Tests for soluble pneumococcal antigen or the direct quellung reaction on sputum have not proved helpful. Pneumococci isolated from blood and spinal fluid should be tested for penicillin sensitivity routinely. Penicillin G and erythromycin are the mainstays of specific treatment, and rapid subjective improvement on narrow-spectrum therapy is an important point in diagnosis. The mortality rate continues to be about 18%, and prevention by vaccination remains a highly desirable goal.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2652234

Source DB:  PubMed          Journal:  Semin Respir Infect        ISSN: 0882-0546


  3 in total

Review 1.  Formulary management of macrolide antibiotics.

Authors:  D R Guay
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

Review 2.  Immunologic tests in the diagnosis of pulmonary infection.

Authors:  E Goldstein; J Koo
Journal:  Clin Rev Allergy       Date:  1990 Summer-Fall

3.  Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia.

Authors:  R Bohte; J W van't Wout; S Lobatto; A Blussé van Oud Alblas; M Boekhout; E H Nauta; J Hermans; P J van den Broek
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.